万达生物制药 VNDA 深 沪
等待开盘 03-26 09:30:00 美东时间
7.25
+0.430
+6.30%
华盛通- 最 高7.27
- 今 开6.92
- 成交量 125.77万股
- 最 低 6.905
- 昨 收 6.82
- 总市值 4.29亿
- 52周最高 9.94
- 市盈率 静 --
- 换手率 2.13%
- 52周最低 3.8092
- 委 比 66.51%
- 总股本 5910.80万
- 历史最高 33.44
- 量 比 0.34
- 振 幅 5.35%
- 历史最低 2.92
- 每 手 1
- 风险率 1.44%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Vanda Pharmaceuticals Advocates For Stronger FDA Measures To Accelerate Shift From Animal Testing To Human-Relevant Methods
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA), a leader in innovative drug development and a vocal advocate for reducing unnecessary animal testing, today voiced serious concerns over the U.S. Food and Drug
03-20 04:39
美股夜盘 | Health In Tech, Inc. Class A涨52.94%，ZenaTech, Inc.涨18.42%
Health In Tech, Inc. Class A涨52.94%；ZenaTech, Inc.涨18.42%；万达生物制药涨10.81%
03-18 13:02
美股夜盘 | Health In Tech, Inc. Class A涨50.00%，Energy Vault涨14.29%
Health In Tech, Inc. Class A涨50.00%；Energy Vault涨14.29%；万达生物制药涨10.58%
03-18 10:02
美股夜盘 | Health In Tech, Inc. Class A涨52.35%，Diginex Ltd.涨13.38%
Health In Tech, Inc. Class A涨52.35%；Diginex Ltd.涨13.38%；万达生物制药涨11.28%
03-18 09:02
美股夜盘 | Health In Tech, Inc. Class A涨27.06%，SHF Holdings Inc Class A涨11.49%
有信科技涨-19.52%；美物科技涨-17.76%；优品车涨-16.52%
03-18 08:13
美股大行评级 | 最高582美元！博通获多家机构上调目标价；GENI、Okta、Rigetti Computing、Veeva Systems、Wix.com遭多家机构下调目标价
今日重点评级关注：韦德布什：维持TScan Therapeutics"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持莱斯康制药"买入"评级，目标价从4美元升至6美元
03-06 11:58
Vanda Wins FDA Hearing in HETLIOZ Jet Lag Approval Dispute
Vanda Wins FDA Hearing in HETLIOZ Jet Lag Approval Dispute Vanda Pharmaceuticals said the FDA has granted its request for a formal evidentiary public hearing to review CDER’s proposal to refuse approval of the company’s supplemental new drug application seeking to expand Hetlioz to treat jet lag dis
03-03 21:09
FDA grants Vanda formal public hearing over proposed HETLIOZ jet lag sNDA refusal
FDA grants Vanda formal public hearing over proposed HETLIOZ jet lag sNDA refusal Vanda Pharmaceuticals said the FDA has granted its request for a formal evidentiary public hearing to review CDER’s proposal to refuse approval of the company’s supplemental application seeking to expand HETLIOZ (tasim
03-03 21:03
FDA Accepts Vanda's New Drug Application For Rare, Life-Threatening Skin Disease
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics License Application (BLA) for imsidolimab for the treatment of
02-25 20:22
What's Going On With Vanda Pharma Stock Tuesday?
FDA's approval of Bysanti boosts Vanda's portfolio, with potential to treat bipolar disorder, schizophrenia, and major depressive disorder.
02-25 01:44
